OBJECTIVE: We aimed to determine to what extent covariate adjustment could affect power in a randomized controlled trial (RCT) of a heterogeneous population with traumatic brain injury (TBI). STUDY DESIGN AND SETTING: We analyzed 14-day mortality in 9,497 participants in the Corticosteroid Randomization After Significant Head Injury (CRASH) RCT ofcorticosteroid vs. placebo. Adjustment was made using logistic regression for baseline covariates of two validated risk models derived from external data (International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury [IMPACT]) and from the CRASH data. The relative sample size (RESS) measure, defined as the ratio of the sample size required by an adjusted analysis to attain the same power as the unadjusted reference analysis, was used to assess the impact of adjustment. RESULTS:Corticosteroid was associated with higher mortality compared with placebo (odds ratio=1.25, 95% confidence interval=1.13-1.39). RESS of 0.79 and 0.73 were obtained by adjustment using the IMPACT and CRASH models, respectively, which, for example, implies an increase from 80% to 88% and 91% power, respectively. CONCLUSION: Moderate gains in power may be obtained using covariate adjustment from logistic regression in heterogeneous conditions such as TBI. Although analyses of RCTs might consider covariate adjustment to improve power, we caution against this approach in the planning of RCTs. Copyright Â
RCT Entities:
OBJECTIVE: We aimed to determine to what extent covariate adjustment could affect power in a randomized controlled trial (RCT) of a heterogeneous population with traumatic brain injury (TBI). STUDY DESIGN AND SETTING: We analyzed 14-day mortality in 9,497 participants in the Corticosteroid Randomization After Significant Head Injury (CRASH) RCT of corticosteroid vs. placebo. Adjustment was made using logistic regression for baseline covariates of two validated risk models derived from external data (International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury [IMPACT]) and from the CRASH data. The relative sample size (RESS) measure, defined as the ratio of the sample size required by an adjusted analysis to attain the same power as the unadjusted reference analysis, was used to assess the impact of adjustment. RESULTS: Corticosteroid was associated with higher mortality compared with placebo (odds ratio=1.25, 95% confidence interval=1.13-1.39). RESS of 0.79 and 0.73 were obtained by adjustment using the IMPACT and CRASH models, respectively, which, for example, implies an increase from 80% to 88% and 91% power, respectively. CONCLUSION: Moderate gains in power may be obtained using covariate adjustment from logistic regression in heterogeneous conditions such as TBI. Although analyses of RCTs might consider covariate adjustment to improve power, we caution against this approach in the planning of RCTs. Copyright Â
Authors: Andrew I R Maas; Anthony Marmarou; Gordon D Murray; Sir Graham M Teasdale; Ewout W Steyerberg Journal: J Neurotrauma Date: 2007-02 Impact factor: 5.269
Authors: Pablo Perel; Miguel Arango; Tim Clayton; Phil Edwards; Edward Komolafe; Stuart Poccock; Ian Roberts; Haleema Shakur; Ewout Steyerberg; Surakrant Yutthakasemsunt Journal: BMJ Date: 2008-02-12
Authors: Kathryn E Saatman; Ann-Christine Duhaime; Ross Bullock; Andrew I R Maas; Alex Valadka; Geoffrey T Manley Journal: J Neurotrauma Date: 2008-07 Impact factor: 5.269
Authors: Ewout W Steyerberg; Nino Mushkudiani; Pablo Perel; Isabella Butcher; Juan Lu; Gillian S McHugh; Gordon D Murray; Anthony Marmarou; Ian Roberts; J Dik F Habbema; Andrew I R Maas Journal: PLoS Med Date: 2008-08-05 Impact factor: 11.069
Authors: Kevin D Hill; H Scott Baldwin; David P Bichel; Alicia M Ellis; Eric M Graham; Christoph P Hornik; Jeffrey P Jacobs; Robert D B Jaquiss; Marshall L Jacobs; Prince J Kannankeril; Jennifer S Li; Rachel Torok; Joseph W Turek; Sean M O'Brien Journal: Am Heart J Date: 2020-05-20 Impact factor: 4.749
Authors: Mieke J Peeters; Arjan D van Zuilen; Jan A J G van den Brand; Michiel L Bots; Marjolijn van Buren; Marc A G J Ten Dam; Karin A H Kaasjager; Gerry Ligtenberg; Yvo W J Sijpkens; Henk E Sluiter; Peter J G van de Ven; Gerald Vervoort; Louis-Jean Vleming; Peter J Blankestijn; Jack F M Wetzels Journal: J Am Soc Nephrol Date: 2013-10-24 Impact factor: 10.121
Authors: Douglas D Thompson; Hester F Lingsma; William N Whiteley; Gordon D Murray; Ewout W Steyerberg Journal: J Clin Epidemiol Date: 2014-11-13 Impact factor: 6.437
Authors: Andrew I R Maas; Gordon D Murray; Bob Roozenbeek; Hester F Lingsma; Isabella Butcher; Gillian S McHugh; James Weir; Juan Lu; Ewout W Steyerberg Journal: Lancet Neurol Date: 2013-10-17 Impact factor: 44.182